NAUT

+ Watchlist + Portfolio

Nautilus Biotechnology, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.90
52-Week Range: $0.62 – $4.31
Market Cap: $114.82M
P/E (TTM): —
EPS (TTM): -0.45
Dividend Yield: —

Advanced Metrics

Price/Book: 0.88
PEG Ratio: —
Return on Equity: -36.21%
Return on Assets: -20.83%
Gross Margin: 92.11%
Operating Margin: -8296.32%
Profit Margin: 0.00%
Current Ratio: 10.14
Debt/Equity: 0.21
Total Debt: $27.82M
Free Cash Flow: $-29.42M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $58.61M

NAUT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$37.67M	$47.25M	$50.48M	$41.11M
Selling, General & Admin	$25.95M	$28.90M	$31.00M	$25.73M
Operating Expenses	$63.62M	$76.15M	$81.48M	$66.84M
Operating Income	-$63.62M	-$76.15M	-$81.48M	-$66.84M
EBITDA	-$60.20M	-$70.45M	-$75.04M	-$60.37M
Pretax Income	-$57.92M	-$63.67M	-$70.78M	-$59.00M
Net Income	-$57.92M	-$63.67M	-$70.78M	-$59.00M
Diluted EPS	-0.46	-0.51	-0.56	-0.47
Diluted Shares	124.59M	124.92M	125.43M	126.26M

NAUT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$114.52M	$19.40M	$27.65M	$12.39M
Current Assets	$187.21M	$176.84M	$132.83M	$105.96M
Total Assets	$350.05M	$305.56M	$242.74M	$191.11M
Current Liabilities	$6.79M	$9.12M	$7.63M	$7.95M
Total Debt	$30.33M	$34.63M	$30.48M	$30.02M
Total Liabilities	$35.13M	$40.21M	$34.01M	$34.14M
Retained Earnings	-$138.56M	-$202.24M	-$273.02M	-$332.02M
Shareholders' Equity	$314.92M	$265.35M	$208.73M	$156.97M
Working Capital	$180.42M	$167.72M	$125.19M	$98.01M

NAUT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$45.81M	-$51.71M	-$59.15M	-$50.70M
Capital Expenditure	-$2.32M	-$2.44M	-$2.12M	-$1.28M
Free Cash Flow	-$48.13M	-$54.15M	-$61.27M	-$51.97M
Depreciation & Amortisation	$3.42M	$5.71M	$6.44M	$6.46M
Stock-Based Compensation	$10.38M	$12.14M	$12.70M	$6.84M
Investing Cash Flow	-$25.74M	-$43.73M	$66.25M	$35.22M
Financing Cash Flow	$562.00K	$368.00K	$1.14M	$214.00K
Net Change in Cash	-$70.98M	-$95.08M	$8.25M	-$15.26M

NAUT Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$10.00K
Cost of Revenue	$0.00	—	—	—	$15.00K
Gross Profit	$0.00	—	—	—	-$5.00K
Research & Development	$10.39M	$9.61M	$9.57M	$9.71M	$9.61M
Selling, General & Admin	$6.70M	$5.87M	$5.85M	$6.42M	$6.33M
Operating Expenses	$17.10M	$15.47M	$15.42M	$16.12M	$15.76M
Operating Income	-$17.10M	-$15.47M	-$15.42M	-$16.12M	-$15.76M
EBITDA	-$15.46M	-$13.85M	-$13.84M	-$14.65M	-$14.48M
Pretax Income	-$15.03M	-$13.57M	-$13.78M	-$14.70M	-$14.47M
Net Income	-$15.03M	-$13.57M	-$13.78M	-$14.70M	-$14.47M
Diluted EPS	-0.12	-0.11	-0.11	-0.12	-0.11
Diluted Shares	126.20M	126.31M	126.37M	126.63M	127.14M

NAUT Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$34.46M	$23.88M	$12.39M	$14.63M	$13.17M
Current Assets	$150.72M	$134.32M	$105.96M	$98.83M	$87.63M
Total Assets	$213.19M	$200.91M	$191.11M	$177.78M	$163.58M
Current Liabilities	$8.14M	$8.98M	$7.95M	$8.34M	$8.64M
Total Debt	$28.18M	$27.00M	$30.02M	$28.87M	$27.82M
Total Liabilities	$32.09M	$31.78M	$34.14M	$33.36M	$32.46M
Retained Earnings	-$304.67M	-$318.24M	-$332.02M	-$346.72M	-$361.19M
Shareholders' Equity	$181.09M	$169.14M	$156.97M	$144.41M	$131.11M
Working Capital	$142.59M	$125.34M	$98.01M	$90.49M	$78.99M

NAUT Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$13.35M	-$11.03M	-$12.38M	-$13.10M	-$13.73M
Capital Expenditure	-$396.00K	-$418.00K	-$244.00K	-$510.00K	-$454.00K
Free Cash Flow	-$13.75M	-$11.45M	-$12.62M	-$13.61M	-$14.18M
Depreciation & Amortisation	$1.63M	$1.62M	$1.59M	$1.48M	$1.28M
Stock-Based Compensation	$1.71M	$1.50M	$1.47M	$1.36M	$1.16M
Investing Cash Flow	$14.47M	$452.00K	$787.00K	$14.23M	$12.02M
Financing Cash Flow	$95.00K	$0.00	$101.00K	$1.10M	$244.00K
Net Change in Cash	$1.22M	-$10.58M	-$11.49M	$2.24M	-$1.46M

Market Snapshot

About

Nautilus Biotechnology, Inc. develops a proteomics platform for analyzing proteins at single-molecule resolution. The company uses proprietary technology to identify and quantify proteins with sensitivity exceeding traditional mass spectrometry methods. Applications include biomarker discovery, therapeutic development, and basic biological research in fields like oncology and neuroscience.